标题：阿魏酸哌嗪辅助治疗糖尿病肾病的效果及对患者肾功能、血液流变学指标的影响

      作者：朱文婧 1，卓宇苗 2，梁钊雄 2    东莞市长安医院内分泌科 1、肾内科 2，广东 东莞 523560

      卷次： 2020年31卷7期

      【摘要】 目的 探讨阿魏酸哌嗪辅助治疗糖尿病肾病(DKD)的效果及对患者肾功能、血液流变学指标的影响。方法 选择东莞市长安医院于2018年1月至2019年1月期间收治的80例早期DKD患者为研究对象，根据随机数表法将患者分为观察组和对照组各40例，对照组患者予厄贝沙坦治疗，观察组联合应用阿魏酸哌嗪治疗，疗程均为3个月。比较两组患者治疗前后的尿白蛋白排泄率(UAER)、血肌酐(Scr)、尿素氮(BUN)以及血液流变学指标(全血黏度及血浆黏度、纤维蛋白原)水平。结果 治疗后，观察组患者的 Scr、BUN、UAER分别为(76.85±19.34) μmol/L、(7.52±1.28) mmol/L、(118.92±30.61) mg/24 h，明显低于对照组的(90.64±22.79) μmol/L、(9.53±1.93) mmol/L、(157.34±29.29) mg/24 h，差异均有统计学意义(P>0.05)；治疗后，观察组患者的血及血浆黏度、纤维蛋白原分别为(4.68±0.94) mPa·s、(1.35±0.26) mPa·s、(3.14±0.73) g/L，明显低于对照组的(5.32±1.21) mPa·s、(1.54±0.31) mPa·s、(3.86±0.82) g/L，差异均有统计学意义(P<0.05)。结论 阿魏酸哌嗪辅助治疗糖尿病肾病可以有效改善患者的血液流变学指标，降低血液黏滞度、改善微循环，降低尿蛋白的排泄，保护患者的肾功能。
      【关键词】 糖尿病肾病；阿魏酸哌嗪；厄贝沙坦；肾功能；血液流变学
      【中图分类号】 R587.2 【文献标识码】 A 【文章编号】 1003—6350（2020）07—0835—03

Effect of piperazine ferulate in adjuvant treatment of diabetic nephropathy and its influence on renal functionand hemorheological parameters of patients.
ZHU Wen-jing 1, ZHUO Yu-miao 2, LIANG Zhao-xiong 2. Department ofEndocrinology 1, Department of Nephrology 2, Dongguan Chang'an Hospital, Dongguan 523560, Guangdong, CHINA
【Abstract】 Objective To investigate the effect of piperazine ferulate on diabetic nephropathy (DKD) and its in-fluence on renal function and hemorheological parameters. Methods Eighty patients with early DKD treated in Dong-guan Chang'an Hospital from January 2018 to January 2019 were selected as the research objects. According to the ran-dom number table, the patients were randomly divided into two groups: the observation group and the control group,with 40 patients in each group. The control group was treated with irbesartan, and the observation group was treated withpiperazine ferulate for three months. Urinary albumin excretion rate (UAER), serum creatinine (Scr), urea nitrogen(BUN), hemorheology (whole blood viscosity, plasma viscosity, and fibrinogen) levels were compared between the twogroups before and after treatment. Results After treatment, Scr, BUN, and UAER in the observation group were(76.85±19.34) μmol/L, (7.52±1.28) mmol/L, (118.92±30.61) mg/24 h, respectively, which were significantly lower than(90.64±22.79) μmol/L, (9.53±1.93) mmol/L, (157.34±29.29) mg/24 h those in the control group (P>0.05). The whole bloodviscosity, and plasma viscosity, and fibrinogen in the observation group were (4.68±0.94) mPa·s, (1.35±0.26) mPa·s, (3.14±0.73) g/L, respectively, which were significantly lower than (5.32±1.21) mPa·s, (1.54±0.31) mPa·s, (3.86±0.82) g/L inthe control group (P<0.05). Conclusion Piperazine ferulate as adjuvant therapy for DKD can effectively improve thehemorheological parameters, reduce blood viscosity, improve microcirculation, reduce urinary protein excretion, and pro-tect the renal function of patients.
      【Key words】 Diabetic nephropathy; Piperazine ferulate; Irbesartan; Renal function; Hemorheology